PBM — PSYENCE BIOMEDICAL LTD.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1985062 ·
Ontario, Canada
Last close
$3.17
Market Cap
$12.09M
52W High
$6.94
52W Low
$2.62
ADV30
80,043
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | — | -1,506,307 | -753,254 | 12,810,145 | 7,149,985 | 943,068 |
| Sep 2024 | 0 | — | -1,157,118 | 141,473 | 2,253,498 | 1,932,519 | 3,508,604 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-58,439,936
Inventory
—
Receivables
$174,187
ST Investments
—
EBIT TTM
$-605,313
Pretax Income TTM
$-611,781
Interest Exp TTM
$6,468
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -5,945,264 | -6,936,421 | 17,567,320 | 623,190 | — | -8,143,007 |
| Mar 2025 | 0 | -3,663,022 | 1,011,790 | 7,316,370 | 594,366 | — | -3,734,238 |
| Mar 2024 | 0 | -43,354,085 | -51,159,048 | 1,132,159 | 12,104,699 | — | -2,945,365 |
| Mar 2023 | 0 | -3,234,869 | -3,206,403 | 1,590,255 | 1,790,700 | — | -1,592,080 |
| Mar 2022 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BLRX | BioLineRx Ltd. | $12.27M | $2.82 | — |
| PHIO | Phio Pharmaceuticals Corp. | $11.91M | $1.02 | — |
| BIOE | Bio Essence Corp | $12.64M | $0.27 | — |
| BIVI | BIOVIE INC. | $11.46M | $1.52 | — |
| CMMB | Chemomab Therapeutics Ltd. | $11.36M | $1.55 | — |
News headlines (Yahoo Finance, 1h cache)
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
2026-05-15 13:15 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-04-27 13:16 · Yahoo
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
2026-04-24 14:19 · Yahoo
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
2026-04-23 11:00 · Yahoo
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
2026-04-20 11:42 · Yahoo
Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness
2026-04-20 11:23 · Yahoo
Trump Trade: President to sign order on psychedelic used for PTSD
2026-04-17 21:56 · Yahoo
Sector Update: Health Care Stocks Advance Late Afternoon
2026-04-17 19:56 · Yahoo
Sector Update: Health Care Stocks Higher Friday Afternoon
2026-04-17 17:44 · Yahoo
Top Midday Gainers
2026-04-17 16:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.